Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCYC Bicycle Therapeutics	$8.00 -1.1%	$7.97	$6.10 ▼ $28.67	$554.03M	1.41	398,061 shs	214,585 shs
IMRA IMARA	$51.35 -0.4%	$17.12	$0.97 ▼ $6.32	$1.35B	1.09	138,364 shs	4,797 shs
OCUL Ocular Therapeutix	$11.03 -0.5%	$8.40	$5.79 ▼ $11.78	$1.76B	1.43	1.43 million shs	2.13 million shs
RIGL Rigel Pharmaceuticals	$18.88 -3.7%	$19.49	$8.61 ▼ $29.82	$337.42M	1.26	210,577 shs	212,770 shs
SPPI Spectrum Pharmaceuticals	$1.03	$1.01	$0.32 ▼ $1.57	$211.41M	2.15	1.93 million shs	N/A

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCYC Bicycle Therapeutics	0.00%	+7.74%	-7.94%	+19.40%	-61.92%
IMRA IMARA	-0.36%	+1.81%	-0.16%	+2.66%	+712.50%
OCUL Ocular Therapeutix	0.00%	+17.84%	+23.24%	+55.13%	+54.05%
RIGL Rigel Pharmaceuticals	0.00%	-0.19%	-11.36%	+13.19%	+119.79%
SPPI Spectrum Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BCYC Bicycle Therapeutics	3.723 of 5 stars	4.4	2.0	0.0	0.0	2.3	4.2	0.6
IMRA IMARA	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
OCUL Ocular Therapeutix	4.0684 of 5 stars	3.5	2.0	0.0	4.1	2.9	2.5	0.0
RIGL Rigel Pharmaceuticals	3.0039 of 5 stars	3.2	0.0	0.0	0.0	2.3	1.7	3.1
SPPI Spectrum Pharmaceuticals	0.444 of 5 stars	0.0	0.0	0.0	4.7	0.6	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCYC Bicycle Therapeutics	2.70	Moderate Buy	$25.00	212.50% Upside
IMRA IMARA	0.00	N/A	N/A	N/A
OCUL Ocular Therapeutix	3.00	Buy	$17.33	57.15% Upside
RIGL Rigel Pharmaceuticals	2.40	Hold	$36.40	92.80% Upside
SPPI Spectrum Pharmaceuticals	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest SPPI, IMRA, OCUL, BCYC, and RIGL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/29/2025	OCUL Ocular Therapeutix	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00
5/7/2025	RIGL Rigel Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$20.00 ➝ $23.00
5/6/2025	OCUL Ocular Therapeutix	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $14.00
5/5/2025	BCYC Bicycle Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Equal Weight ➝ Equal Weight	$15.00 ➝ $17.00
5/2/2025	BCYC Bicycle Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$35.00 ➝ $32.00
5/2/2025	BCYC Bicycle Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$17.00 ➝ $14.00
5/2/2025	BCYC Bicycle Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$26.00 ➝ $22.00
5/2/2025	BCYC Bicycle Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$29.00 ➝ $29.00
5/1/2025	BCYC Bicycle Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$40.00 ➝ $15.00

(Data available from 7/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCYC Bicycle Therapeutics	$25.72M	21.54	N/A	N/A	$11.48 per share	0.70
IMRA IMARA	N/A	N/A	$0.68 per share	75.24	$3.44 per share	N/A
OCUL Ocular Therapeutix	$63.72M	27.58	N/A	N/A	$2.01 per share	5.49
RIGL Rigel Pharmaceuticals	$203.08M	1.66	$1.08 per share	17.50	$0.19 per share	99.37
SPPI Spectrum Pharmaceuticals	$10.11M	20.91	N/A	N/A	$0.15 per share	6.87

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCYC Bicycle Therapeutics	-$169.03M	-$3.14	N/A	N/A	N/A	-790.07%	-25.54%	-21.23%	8/5/2025 (Estimated)
IMRA IMARA	$1.49M	$0.05	1,027.21	∞	N/A	N/A	2.12%	2.00%	N/A
OCUL Ocular Therapeutix	-$193.51M	-$1.15	N/A	N/A	N/A	-323.09%	-59.92%	-41.98%	8/6/2025 (Estimated)
RIGL Rigel Pharmaceuticals	$17.49M	$2.07	9.12	17.98	N/A	18.31%	-655.26%	24.47%	8/5/2025 (Estimated)
SPPI Spectrum Pharmaceuticals	-$75.40M	-$0.36	N/A	14.71	N/A	N/A	-218.44%	-66.16%	N/A

Latest SPPI, IMRA, OCUL, BCYC, and RIGL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2025	Q2 2025	OCUL Ocular Therapeutix	-$0.35	N/A	N/A	N/A	$13.12 million	N/A
8/5/2025	Q2 2025	BCYC Bicycle Therapeutics	-$0.95	N/A	N/A	N/A	$9.43 million	N/A
8/5/2025	Q2 2025	RIGL Rigel Pharmaceuticals	$1.42	N/A	N/A	N/A	$64.58 million	N/A
5/6/2025	Q1 2025	RIGL Rigel Pharmaceuticals	$0.14	$0.63	+$0.49	$0.63	$43.87 million	$53.33 million
5/1/2025	Q1 2025	BCYC Bicycle Therapeutics	-$0.86	-$0.88	-$0.02	-$0.88	$8.67 million	$9.98 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCYC Bicycle Therapeutics	N/A	N/A	N/A	N/A	N/A
IMRA IMARA	N/A	N/A	N/A	N/A	N/A
OCUL Ocular Therapeutix	N/A	N/A	N/A	N/A	N/A
RIGL Rigel Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SPPI Spectrum Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCYC Bicycle Therapeutics	N/A	14.86	14.86
IMRA IMARA	N/A	48.98	48.98
OCUL Ocular Therapeutix	0.26	10.22	10.14
RIGL Rigel Pharmaceuticals	2.42	2.20	2.13
SPPI Spectrum Pharmaceuticals	N/A	2.71	2.38

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BCYC Bicycle Therapeutics	86.15%
IMRA IMARA	49.28%
OCUL Ocular Therapeutix	59.21%
RIGL Rigel Pharmaceuticals	66.23%
SPPI Spectrum Pharmaceuticals	21.67%

Insider Ownership

Company	Insider Ownership
BCYC Bicycle Therapeutics	22.90%
IMRA IMARA	37.30%
OCUL Ocular Therapeutix	2.30%
RIGL Rigel Pharmaceuticals	9.48%
SPPI Spectrum Pharmaceuticals	2.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BCYC Bicycle Therapeutics	240	69.25 million	53.40 million	Optionable
IMRA IMARA	41	26.23 million	16.45 million	Not Optionable
OCUL Ocular Therapeutix	230	159.30 million	155.64 million	Optionable
RIGL Rigel Pharmaceuticals	160	17.87 million	16.18 million	Optionable
SPPI Spectrum Pharmaceuticals	86	205.25 million	199.70 million	Optionable

SPPI, IMRA, OCUL, BCYC, and RIGL Headlines

Recent News About These Companies

IDMC Provides Positive Recommendation for Bio-Thera Solution's BAT4406F (ADCC-Enhanced Anti-CD20 mAb) in Neuromyelitis Optica Spectrum Disorder Based on Interim Analysis of Pivotal Phase II/III Trial

July 2, 2025 | prnewswire.com

Pneumagen Announces Peer-Reviewed Publication of Positive Phase II Study Data Highlighting the Potential of Neumifil, a Novel Broad-Spectrum Antiviral

July 2, 2025 | globenewswire.com

There is a Strong Business Case for Phase II Clinical Program for Treatment of MPox Infection Using NV-387, an Industry-Leading Broad-Spectrum Antiviral Drug Candidate

July 1, 2025 | accessnewswire.comA

Osivax Announces Last Patient Last Visit in Phase 2a Trial Evaluating a Booster Dose of Broad-Spectrum Influenza Vaccine OVX836 s release

June 5, 2025 | globenewswire.com

Broad-Spectrum Antiviral Drug NV-387 Cleared for Phase II Clinical Trial Application by the National Ethics Committee of the Democratic Republic of Congo

May 8, 2025 | accessnewswire.comA

Bio-Thera Solutions Publishes Phase I Clinical Study Results for BAT4406F, an ADCC-Enhanced Fully Humanized Anti-CD20 Monoclonal Antibody, in Patients with Neuromyelitis Optica Spectrum Disorders

January 14, 2025 | prnewswire.com

Non-Hodgkin’s Lymphoma Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers

November 4, 2024 | theglobeandmail.com

Spectrum Thin Films, Inc.

October 31, 2024 | optics.orgO

India – Key Considerations For Patenting Nutraceuticals/Dietary Supplements.

October 10, 2024 | conventuslaw.comC

Qylur Awarded SBIR Phase II Contract for a Tactical AI Spectrum Classifier Systems (TASCS)

October 2, 2024 | globenewswire.com

NanoViricides prepares for Phase II trial of broad-spectrum antiviral NV-387

August 19, 2024 | proactiveinvestors.com

GPC Biotech Announces Granting of European Patent Related to Satraplatin for Treating Tumors Resistant or Refractory to Taxanes

August 19, 2024 | br.advfn.com

Global AL Amyloidosis Therapeutics Market Set for Remarkable Growth, Projected to Reach USD 4.56 Billion by 2033

July 31, 2024 | fmiblog.comF

Company History - Paam Drugs and Pharmaceuticals

July 19, 2024 | moneycontrol.com

STALICLA publishes pioneering phase 1b data on precision treatment for autism spectrum disorder in Biomedicines

June 27, 2024 | globenewswire.com

Osivax Completes Enrollment for Phase 1 Trial with Broad-Spectrum Sarbecovirus Vaccine Candidate, OVX033

June 25, 2024 | businesswire.com

Pneumagen Presents Positive Phase 2 Influenza Human Challenge Study data on Neumifil, its Broad-Spectrum Antiviral Drug, at the American Thoracic Society (ATS) 2024 Conference

May 23, 2024 | globenewswire.com

Pneumagen to Present Phase 2 Clinical Data on Neumifil, its Broad-Spectrum Antiviral, Intranasal Drug for Viral Respiratory Tract Infections, at ATS 2024

May 2, 2024 | globenewswire.com

Spectrum Pharmaceuticals gets grant for crystalline form of quinazoline compound and hydrochloride salts

April 24, 2024 | pharmaceutical-technology.comP

Assertio Holdings, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information - ASRT

February 21, 2024 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPPI, IMRA, OCUL, BCYC, and RIGL Company Descriptions

Bicycle Therapeutics NASDAQ:BCYC

$8.00 -0.09 (-1.11%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$7.50 -0.51 (-6.31%)

As of 07/11/2025 04:29 PM Eastern

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

IMARA NASDAQ:IMRA

IMARA Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. Its lead product candidate is IMR-687, an oral and once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia. The company also develops IMR-261, an oral and clinical-ready activator of nuclear factor erythroid 2-related factor 2 for the treatment of hemoglobinopathies, iron disorders, and potentially other areas. IMARA Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Ocular Therapeutix NASDAQ:OCUL

$11.03 -0.05 (-0.45%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$11.08 +0.04 (+0.41%)

As of 07/11/2025 07:38 PM Eastern

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

Rigel Pharmaceuticals NASDAQ:RIGL

$18.88 -0.72 (-3.67%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$18.92 +0.05 (+0.24%)

As of 07/11/2025 04:34 PM Eastern

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.

Spectrum Pharmaceuticals NASDAQ:SPPI

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products. It offers ROLVEDON(Eflapegrastim), a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia. The company develops Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and license agreement with Therapyx, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time